NCT06243679View on ClinicalTrials.gov

The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

September 1, 2027

Study Completion Date

December 1, 2027

Conditions
Resectable/Potentially Resectable NSCLC
Interventions
DRUG

Immunotherapy

Monotherapy with PD-1 inhibitors, up to 1 year.

Trial Locations (1)

410008

Xiangya Hospital, Central South University Affiliated, Changsha

All Listed Sponsors
lead

Xiangya Hospital of Central South University

OTHER